The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women
- 110 Downloads
Laquinimod is an orally dosed immuno-modulator currently under development for Huntington’s disease (HD). Preclinical findings suggest potential teratogenicity of laquinimod, thus the reproductive ability of females with HD treated with laquinimod needs to be closely managed. Because combined oral contraceptives (COC) are often used in this context, the pharmacokinetics of COC containing ethinylestradiol (EE) and levonorgestrel (LNG) in combination with laquinimod (0.6 mg/day) was evaluated.
In this randomized, phase-1 single-center, double-blind, placebo-controlled, 2-way crossover drug-drug interaction (DDI) study in 48 healthy premenopausal women, COC were administered in a 28-day regimen of 21 days followed by 7 pill-free days for 4 cycles and laquinimod or placebo was administered for 28 days in cycle 1 and cycle 3 starting 7 days prior to COC administration. Blood samples for pharmacokinetic profiling of laquinimod, EE and LNG were collected on day 21 and day 22 of Cycles 1 and 3 pre-dose and multiple times post-dose.
The ratio of geometric means and 90% confidence intervals for AUC0-24 and Cmax of EE and LNG with and without laquinimod were all within the bioequivalence range (80 to 125%). Laquinimod pharmacokinetics was consistent with those observed in previous studies. The adverse event profile was in line with the current knowledge on the safety profile of both drugs, with headache as the most frequently reported treatment-related adverse event.
The combination of COC and laquinimod treatment was found to be safe, tolerable, and devoid of any noticeable pharmacokinetic interaction.
KeywordsLaquinimod Huntington’s disease Pharmacokinetics Oral contraceptive Drug-drug interaction
The authors thank the principal investigator Irina Remez MD, CRS Clinical Research Services Mönchengladbach GmbH, Mönchengladbach Germany. Sandeep Gopalam, M. Pharmacy (Pharmaceutics); Geetha Range Gowda, B.E (Biotechnology) from Lotus Labs Pvt. Ltd.; and Pippa Loupe PhD (Global Research and Development, Teva Pharmaceutical Industries, Overland Park KS) for assistance with manuscript preparation.
Compliance with ethical standards
Conflict of interest
Authors AE, AZ, DM, VD, OBI and OS are employees of Teva Pharmaceuticals Ltd. who are sponsoring the clinical development of laquinimod for Huntington’s disease. TK was a consultant for Teva Pharmaceutics at the time the study was conducted.
Research involving humans and informed consent
The study was carried out in compliance with the Declaration of Helsinki and International Council on Harmonization (ICH) Good Clinical Practice (E6) Guidelines and applicable national and local laws and regulations. The study was initiated after receiving approval from Independent Ethics Committee (IEC) Ethikkommission der Ärztekammer Nordrhein, Düsseldorf Germany, and from national or local regulations of the competent health authorities. All the subjects gave their written consent for voluntary participation.
- 6.Garcia-Miralles M, Hong X, Juin Tan L, Caron N, Huang Y, Toe XV et al (2016) Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease. Sci Rep 6:31652. https://doi.org/10.1038/srep31652 CrossRefGoogle Scholar
- 7.Kay C, Hayden MR, Leavitt BR (2017) Epidemiology of Huntington disease. Handb Clin Neurol 144:31–46. https://doi.org/10.1016/B978-0-12-801893-4.00003-1 CrossRefGoogle Scholar
- 11.Spiegelstein O, Dorit Mimrod D, Rabinovich L, Eyal E, Sprenger C, Elgart A et al (2018) A thorough QT/QTc study with laquinimod, a novel immunomodulator in development for multiple sclerosis and Huntington disease. Clin Pharmacol Drug Dev 0(0):1–18 online versionGoogle Scholar
- 13.Kaye J, Piryatinsky V, Birnberg T, Hingaly T, Raymond E, Kashi R, Amit-Romach E, Caballero IS, Towfic F, Ator MA, Rubinstein E, Laifenfeld D, Orbach A, Shinar D, Marantz Y, Grossman I, Knappertz V, Hayden MR, Laufer R (2016) Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor. Proc Natl Acad Sci USA 113:E6145–E6152CrossRefGoogle Scholar
- 15.US Health and Human Services, FDA CDER (2012) Draft guidance for industry on drug interaction studies: study design, data analysis, implications for dosing, and labeling recommendations. https://www.gpo.fdsys/granule/FR-2012-02-21/2012-3958. Accessed 19 Jan 2018
- 18.Maitra N, Kulier R, Bloemenkamp KW, Helmerhorst FM, Gülmezoglu AM (2004) Progestogens in combined oral contraceptives for contraception. Cochrane Database Syst Rev 3:CD004861Google Scholar
- 19.Sennbro CJ, Olin M, Edman K, Hansson G, Gunnarsson PO, Sevnsson LD (2006) Determination of the immunomodulator laquinimod in human plasma by liquid chromatography/tandem mass spectrometry; development, validation and application of two methods in clinical pharmacokinetic profiling. Rapid Commun Mass Spectrom 20:3313–3318CrossRefGoogle Scholar
- 20.Guengerich FP (1988) Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. Mol Pharmacol 33:500–508Google Scholar
- 26.Labeling for Combined Hormonal Contraceptives Guidance for Industry Draft 2017. https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm590673.pdf. Accessed 5 Feb 2018
- 27.ALESSE® 28 Tablets Alesse Package Insert. Wyeth Pharmaceuticals https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020683s004s006s007lbl.pdf. Accessed 4 April 2018
- 28.Nizoral (ketoconazole) Tablets package insert (2013) Janssen Pharmaceuticals, USFDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018533s040lbl.pdf. Accessed 19 Jan 2018
- 29.Blode H, Zeun S, Parke S, Zimmermann T, Rohde B, Mellinger U, Kunz M (2012) Evaluation of the effects of rifampicin, ketoconazole and erythromycin on the steady-state pharmacokinetics of the components of a novel oral contraceptive containing estradiol valerate and dienogest in healthy postmenopausal women. Contraception 86:337–344CrossRefGoogle Scholar
- 30.U.S. Department of Health and Human Services Food and Drug Administration (2017) Center for Drug Evaluation and Research (CDER) Clinical Drug Interaction Studies — study design, data analysis, and clinical implications guidance for industry. https://www.fda.gov/downloads/drugs/guidances/ucm292362.pdf. Accessed 10 Aug 2018